Clinical Trial Update: Study of AAV-GAD Gene Transfer Into the Subthalamic Nucleus for Parkinson's Disease [Phase 2]

View source ↗

Summary

A Phase 2 trial evaluating AAV-GAD gene transfer into the subthalamic nucleus for Parkinson's disease has been terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Parkinson Disease

Drugs mentioned

• AAV-GAD gene transfer

Snippet

Sponsor: Neurologix, Inc. | Conditions: Parkinson's Disease | Phase 2 | Status: TERMINATED